RecruitingPhase 3NCT06846086
Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
A Clinical Study to Assess the Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
Sponsor
Tanta University
Enrollment
46 participants
Start Date
Feb 20, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of current study is to: Evaluate the cardioprotective effects of melatonin in patients with cardiomyopathy.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Adult patients (≥18 years) with a confirmed diagnosis of cardiomyopathy based on clinical, echocardiographic, or imaging findings. .
- Stable condition on standard cardiomyopathy medications (e.g., ACE inhibitors, beta-blockers).
- Ability to provide informed consent.
Exclusion Criteria7
- Recent hospitalization for cardiomyopathy exacerbation (within the last 3 months).
- Severe kidney or liver impairment.
- Use of other investigational drugs or antioxidants.
- Pregnancy or planning to be pregnant in the next 6 months
- Previous known hypersensitivity to melatonin.
- Presence of atrial fibrillation or other significant arrhythmias at baseline.
- Participation in another research.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMelatonin 10 MG
Melatonin
DRUGPlacebo
placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06846086
Related Trials
Mayo AVC Registry and Biobank
NCT030492542 locations
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT0615869810 locations
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
NCT053022711 location
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
NCT0589071614 locations
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT0656389598 locations